Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'The evidence is out there…': perspectives of healthcare providers on improving asthma and COPD prevention and care within a major health authority region of British Columbia, Canada.

BMJ open quality·2026
Same author

Using cell-specific late-phase asthma mRNA biomarkers to repurpose drugs that concurrently reverse disease signatures across multiple immune cell-types.

PLoS computational biology·2026
Same author

Real-world Persistence on Selexipag for Pulmonary Arterial Hypertension in Canada.

CJC open·2026
Same author

Study of angiogenic cell therapy for progressive pulmonary arterial hypertension: intervention with repeat dosing of eNOS-enhanced EPCs: the SAPPHIRE trial.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same author

Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.

The European respiratory journal·2024
Same author

Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis.

Pragmatic and observational research·2024
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
Same journal

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept.

Chest·2026
Same journal

Eisenmenger Syndrome: The Pulmonology Perspective.

Chest·2026
Same journal

Phenotyping of pulmonary arterial hypertension associated with congenital heart disease using latent class analysis: insights from a national prospective registry.

Chest·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins in COPD: a systematic review.

Surinder Janda1, Kirly Park1, J Mark FitzGerald1

  • 1Department of Medicine, University of British Columbia, Vancouver, BC, Canada.

Chest
|April 21, 2009
PubMed
Summary
This summary is machine-generated.

Statins may benefit patients with chronic obstructive pulmonary disease (COPD), improving outcomes like exacerbations and mortality. Further prospective trials are needed to confirm these benefits in COPD management.

Related Experiment Videos

Last Updated: Jun 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pulmonology
  • Pharmacology

Background:

  • Statins (3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors) are common for hypercholesterolemia and cardiovascular disease.
  • Emerging evidence suggests statins may reduce morbidity and mortality in COPD patients.

Purpose of the Study:

  • To systematically review existing literature on the effects of statin therapy on COPD patient outcomes.

Main Methods:

  • Searched Medline, EMBASE, PapersFirst, and Cochrane databases.
  • Included randomized controlled trials (RCTs), observational cohort studies, case-control studies, and population-based analyses.

Main Results:

  • Nine studies were reviewed (4 retrospective cohorts, 1 nested case-control, 1 retrospective cohort/case series, 2 population-based analyses, 1 RCT).
  • All studies indicated benefits of statins for COPD outcomes, including reduced exacerbations, fewer/delayed intubations, improved pulmonary function, enhanced exercise capacity, and lower COPD-related and all-cause mortality.
  • No studies reported negative or neutral effects of statins on COPD outcomes.

Conclusions:

  • Current literature suggests statins may benefit COPD treatment.
  • However, most studies are retrospective and have methodological limitations.
  • Prospective interventional trials are needed to specifically assess statin impact on clinically relevant COPD outcomes.